Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy
Launched by OHIO STATE UNIVERSITY · Feb 23, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how spinal cord stimulation (SCS) may help people with diabetic peripheral neuropathy (DPN), a condition that can cause painful nerve damage in the feet and legs due to diabetes. The study will enroll participants who have been struggling with pain despite trying multiple medications. They will be placed into one of three groups: two groups will receive different types of treatment involving spinal cord stimulation, while the third group will not receive the treatment and will act as a control.
To be eligible for this trial, participants must be over 18 years old and have had significant pain for at least a year that hasn't improved with standard pain medications. They should also be able to understand the study and give their consent to participate. Throughout the trial, participants will be monitored to see how their pain levels, nerve activity, and overall health change before and after the spinal cord stimulation treatment. This research could provide valuable insights into new ways to manage pain for those with diabetic neuropathy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 years old
- • Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic
- • Diagnosis of medically refractory pain secondary to diabetic neuropathy
- • Presence of pain for 12 months
- • Lower limb pain intensity score ≥4 on a visual analog scale
- • DN4 ≥4
- • Pass pre-operative neuropsychological assessment (surgical group only)
- • Capable of providing informed consent
- Exclusion Criteria:
- • Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention
- • Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement
- • Coagulopathy that cannot be corrected
- • Unable to discontinue blood thinning medications
- • Hemoglobin A1c level greater than 10
- • Presence of systemic infection
- • Pregnancy
About Ohio State University
The Ohio State University (OSU) is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a commitment to improving patient care and outcomes, OSU leverages its extensive resources, interdisciplinary collaboration, and expertise in diverse medical fields. The university fosters an environment of rigorous scientific inquiry, ensuring that clinical trials are conducted with the highest ethical standards and adherence to regulatory guidelines. Through its Clinical Trials Office, OSU aims to translate groundbreaking research into practical applications, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Brian Dalm, MD
Principal Investigator
Ohio State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported